Gilead Sciences, Leerink
Gilead Sciences (NASDAQ:GILD) Upgraded to “Strong-Buy” at Leerink Partnrs
Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number of other analysts also recently commented on GILD.
Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...
Barchart on MSN1d
Gilead Sciences’ Quarterly Earnings Preview: What You Need to KnowGilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
GlobalData on MSN21h
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback